The global Soliris drug market is expected to grow at a significant CAGR during the forecast period. The key factor contributing to the growth of the global Soliris Drug market includes the rising prevalence of chronic rare disorders such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized Myasthenia Gravis (gMG), and many more. According to the European Journal of Human Genetics 2019, around 4% of the global population suffers from a rare disease.

Soliris (eculizumab) is a monoclonal antibody intended to treat rare disorders such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized Myasthenia Gravis (gMG). Eculizumab binds to proteins in the blood that can cause red blood cells to die in persons who have hereditary disorders that weaken red blood cell defences. Soliris (eculizumab) is manufactured by Alexion Pharmaceuticals and was approved by US FDA in 2007 for the treatment of PNH and in 2011 for the treatment of aHUS. Many companies are in clinical trials for a biosimilar of the Soliris. For instance, in January 2021, ABP 959, a biosimilar of Soliris (eculizumab), entered into the phase 3 clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

Alexion Pharmaceuticals Inc. is developing a new line of therapies for the treatment of rare diseases using Soliris (eculizumab). For instance, in June 2019, Alexion Pharmaceuticals Inc. announced the approval of Soliris (eculizumab) by the US FDA for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults’ patients who are anti-aquaporin-4 (AQP4) antibody positive.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Type

o By Application

• Regions covered-

o North America

o Europe

o Asia Pacific

o Rest of the World

• Competitive Landscape- Alexion Pharmaceuticals Inc. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Soliris Drug Market by Segments

By Type

• Plasma Exchange
• Plasma Infusion

By Application

• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• atypical Hemolytic Uremic Syndrome (aHUS)
• Myasthenia Gravis
• Neuromyelitis Optica Spectrum Disorder
• Other

Global Soliris Drug Market by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa